Back

Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk scores in cardio-oncology Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Assessment of ESC risk stratification for cancer therapy-related cardiovascular toxicity in a real-world urban population
Doctor J. Arnold (Chicago, US)
Abstract Slides
Presentation thumbnail
Accurate and efficient cardio-oncology outpatient clinic summarization with open-source large language models for non-english text
Doctor J. Heemelaar (Leiderdorp, NL)
Abstract Slides
Presentation thumbnail
Hepcidin and cardiovascular events in patients with chronic kidney disease undergoing dialysis: a post-hoc analysis of the ASCEND-D trial
Doctor Y. Fujimoto (Tokyo, JP)
Abstract Slides
Presentation thumbnail
The new mechanism of apatinib in treating gastric cancer-related hypertension: dynamin-related protein 1-mediated pathological mitochondrial fission in endothelial cells
Doctor F. Si (Lanzhou, CN)
Abstract Slides
Presentation thumbnail
The diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune checkpoint inhibitor therapy.
Associate Professor C. Ayoub (Phoenix, US)
Abstract Slides

Access the full session

Session thumbnail
Risk scores in cardio-oncology

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources